Portfolio Company · Operating Co.
Trishula Therapeutics logo

Trishula Therapeutics

CurrentHealthcare
Trishula Therapeutics
a portfolio company of
Canaan Partners
Status on record: Current
PE Firm Index

Who owns Trishula Therapeutics?

Trishula Therapeutics is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

From the company's website

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class anti-CD39 antibody.

Source: trishulatx.com, read November 2026

Company Snapshot

Trishula Therapeutics is a Healthcare company. Its owner on record, Canaan Partners, is a firm. Canaan Partners lists 349 companies in the index, 17 of them in Healthcare.

Parent PE firmCanaan Partners
Ownership statusCurrent
WebsiteVisit ↗

About the owner

Questions about Trishula Therapeutics

Who owns Trishula Therapeutics?

Trishula Therapeutics is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

What sector is Trishula Therapeutics in?

Trishula Therapeutics is in Healthcare. Classified from the company's own description.

What else does Canaan Partners own in Healthcare?

Canaan Partners lists 16 other Healthcare companies in the index, including Acesion Pharma ApS, Agomab Therapeutics, Alphina Therapeutics, Alterome Therapeutics, Inc. and Amicus Therapeutics.

What is Trishula Therapeutics' website?

Trishula Therapeutics' website is https://www.trishulatx.com/.

Sources

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Trishula Therapeutics and does not provide investment advice.

Other portfolio companies of Canaan Partners

6 of 348 shown

See the full Canaan Partners portfolio.

Other Healthcare companies held by Canaan Partners

Other Healthcare portfolio companies

Browse PE-backed companies.